Anti-BCMA CAR mRNA-LNP
BCMA (B cell maturation antigen), also known as CD269, TNFRSF-17, is an ideal target antigen for novel multiple myeloma therapy due to its highly selective expression in malignant plasma cells. BCMA is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor and is encoded by the human TNFRSF17 gene. This receptor is preferentially expressed on mature B lymphocytes and is important for B cell development and autoimmune responses. This receptor has been shown to specifically bind tumor necrosis factor (ligand) superfamily member 13b (TNFSF13B/TALL-1/BAFF), leading to activation of NF-κB and MAPK8/JNK. For targeting BCMA, chimeric antigen receptor (CAR)-modified T-cell therapy is one of the most common treatment modalities. This product is designed as a tool for the delivery and expression of anti-BCMA CAR mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of anti-BCMA CAR mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The anti-BCMA CAR in this product is approximately 56 kD and consists of anti-BCMA scFv (single-chain variable fragment) linked to a second-generation CAR (chimeric antigen receptor) containing the CD8 hinge and transmembrane domain and 4-1BB and CD3ζ signaling domains. The full-length amino acid sequence of this anti-BCMA CAR mRNA-LNP product is available upon request.